Demo Use Cases
Real-world financial analysis examples using Aevorex MCP connector. See how natural language queries access 80+ financial tools with live data.
Live Examples
Real Use Cases
Complete crypto market analysis using Aevorex MCP connector with live data from multiple sources.
📊 Crypto Market Weekly Update - November 4, 2025
What happens in the crypto market as of today? Only use the Aevorex MCP connector data.
User Query:
"What happens in the crypto market as of today? Only use the Aevorex MCP connector data. Weekly update"
🔴 Market Sentiment: Consolidation & Volatility
The crypto market is experiencing a correction phase this week, with significant selling pressure across major assets and crypto-related equities.
💰 Key Crypto Proxies Performance (Oct 28 - Nov 3)
Coinbase (COIN.US) - Leading Crypto Exchange
• Week Performance: -6.99% (from $355.22 to $330.42)
• Volatility: High volume spike on Oct 31 (13.8M shares)
• Low Point: $325.88 on Nov 3
• Signal: Institutional selling pressure evident
MicroStrategy (MSTR.US) - Bitcoin Treasury Company
• Week Performance: -7.02% (from $284.64 to $264.67)
• Volatility: Massive volume on Oct 30 (15.6M shares vs avg 10M)
• Low Point: $254.57 on Oct 30
• Signal: Bitcoin proxy showing weakness
📰 Regulatory & Policy News
Major Development: Crypto's regulatory breakthrough continues from August 21, 2025:
✅ Achievements:
• $200M+ spent by crypto industry on pro-blockchain political candidates
• Genius Act passed - establishes stablecoin guardrails
• Strategic Bitcoin Reserve - created via executive order
• SEC overhaul - new leadership under Chair Paul Atkins launching "Project Crypto"
⚠️ Pending Legislation:
• Clarity Act: ~60% chance of passing within next year
• House passed, Senate still deliberating
• Sentiment Score: 0.991 (Highly Positive) - extremely bullish regulatory environment
🏦 Macro Economic Context
• Fed Funds Rate: 4.09% (Restrictive monetary policy persists)
• Eurozone Inflation (Oct 2025): HICP 2.1% YoY
• Eurozone Unemployment (Sep 2025): 6.34%
• US Treasury Yield Curve: 3M: 3.98% | 2Y: 3.60% | 10Y: 4.13% | 30Y: 4.69%
• Shape: Inverted short-end, steepening long-end
🎯 Key Takeaways
• Price Action: Crypto-related stocks down ~7% this week
• Regulatory Environment: Extremely favorable - best positioning in crypto history
• Macro Headwinds: High interest rates (4%+) continue to pressure risk assets
• Institutional Activity: Volume spikes suggest active repositioning
• Political Support: Trump administration + bipartisan Congress = strong tailwinds
⚡ Outlook
• Short-term: Consolidation likely continues
• Medium-term: Regulatory clarity could trigger next leg up
• Long-term: Strategic Bitcoin Reserve + institutional adoption = structurally bullish
Data Sources: Aevorex MCP Connector (EODHD, US Treasury, ECB, FRED API)
Last Updated: November 4, 2025, 13:52 UTC
💊 Novo Nordisk Analysis
Combined news and technical analysis using macro, news, fed, and EODHD MCP tools.
💊 Novo Nordisk Deep Dive - Last 2 Days
Using MCP tools: macro, news, fed, EODHD to analyze what happened with Novo Nordisk
User Query:
"Use the MCP tools: macro, news, fed, EODHD macro news etc to tell me what has happened with Novo Nordisk, compare with technical analysis. Only in the last 2 days!"
📰 News Summary (Nov 5-6, 2025)
Major Developments:
Trump Administration Drug Pricing Deal (Nov 6)
• Novo Nordisk and Eli Lilly reached agreements with Trump administration to slash GLP-1 drug prices
• Wegovy & Ozempic available to Medicare/Medicaid patients for $245/month (down from $1,000+)
• Novo gets 3-year tariff exemption in exchange
• Direct-to-consumer pricing: Wegovy pill at $149/month, injectable at $499/month
• Expected impact: Low single-digit negative impact on 2026 global sales growth
Q3 Earnings Disappointment (Nov 5)
• Lowered full-year guidance for the 4th time in 2025
• Sales growth outlook cut to 8-11% (from 8-14%)
• Operating profit growth cut to 4-7% (from 4-10%)
• Reason: Slowing demand for GLP-1 treatments amid intensifying competition
Metsera Bidding War
• Court denied Pfizer's request to block Novo's $10 billion bid for obesity startup Metsera
• Novo raised bid to $10 billion ($86.20/share), Pfizer matched it
💹 Technical Analysis (Last 2 Days)
Price Action:
• Nov 5: Opened at $47.75, closed at $47.19
• Change: Down -2.62% (-$1.27)
• Range: $46.36 (low) to $49.56 (high)
• Volume: 36.2 million (elevated, indicating heavy selling pressure)
• Previous close: $48.46
Key Observations:
• Stock gapped down after Q3 earnings miss
• Briefly recovered to $49.56 on Medicare pricing relief news
• Closed near session lows, showing bearish sentiment
• YTD performance: Down ~46% (stock has lost half its value)
🎯 Bottom Line
The news is bearish (guidance cuts, competition, pricing pressure), and the technical action confirms it (down 2.6%, near lows, high volume). The Medicare deal provides some relief but isn't enough to offset structural headwinds.
Data Sources: Aevorex MCP Connector (Company News, Technical Indicators, Live Price Data)
Analysis Period: November 5-6, 2025
Ready to Try It Yourself?
These examples show the power of Aevorex MCP connector with real financial data analysis. Set up your preferred AI platform and start exploring.